Targeting glucose metabolism in patients with cancer

Cancer

Volumn 120, Issue 6, 2014, Pages 774-780

  Elf, Shannon E ^a   Chen, Jing ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anticancer targets; cancer metabolism; metabolic enzymes; small molecule inhibitors; the Warburg effect

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; ASPARAGINASE; FLUOROURACIL; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHOTREXATE; PGMI 004A; PHOSPHOGLYCERATE MUTASE; PHOSPHOGLYCERATE MUTASE 1; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALOPECIA; ANTIPROLIFERATIVE ACTIVITY; BONE MARROW SUPPRESSION; CANCER CELL; CELL METABOLISM; CENTRAL NERVOUS SYSTEM DISEASE; COLON CANCER; DRUG CYTOTOXICITY; DRUG TARGETING; GLIOMA; GLUCOSE METABOLISM; GLYCOLYSIS; HEAD AND NECK CANCER; HUMAN; LIPOGENESIS; LIVER DYSFUNCTION; MOLECULARLY TARGETED THERAPY; NAUSEA AND VOMITING; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PANCREATITIS; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SECOND CANCER;

ANTICANCER TARGETS; CANCER METABOLISM; METABOLIC ENZYMES; SMALL-MOLECULE INHIBITORS; THE WARBURG EFFECT;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL PROLIFERATION; ENERGY METABOLISM; GLUCOSE; GLYCOLYSIS; HUMANS; NEOPLASMS;

EID: 84896716045     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28501     Document Type: Review

References (50)

1. Warburg O,. On the origin of cancer cells. Science. 1956; 123: 309-314.
2. Cairns RA, Harris IS, Mak TW,. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11: 85-95.
3. Kroemer G, Pouyssegur J,. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008; 13: 472-482. (Pubitemid 351766797)
4. Vander Heiden MG, Cantley LC, Thompson CB,. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324: 1029-1033.
5. Ward PS, Thompson CB,. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012; 21: 297-308.
6. DeVita VT Jr, Chu E,. A history of cancer chemotherapy. Cancer Res. 2008; 68: 8643-8653.
7. Kaye SB,. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer. 1998; 78 (suppl 3): 1-7. (Pubitemid 128710590)
8. Meyer LM, Miller FR, Rowen MJ, Bock G, Rutzky J,. Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid). Acta Haematol. 1950; 4: 157-167.
9. Broome JD,. L-Asparaginase: discovery and development as a tumor-inhibitory agent. Cancer Treat Rep. 1981; 65 (suppl 4): 111-114. (Pubitemid 13243416)
10. Vander Heiden MG,. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011; 10: 671-684.
11. Cairo MS,. Adverse reactions of L-asparaginase. Am J Pediatr Hematol Oncol. 1982; 4: 335-339. (Pubitemid 13197854)
12. Hatzivassiliou G, Zhao F, Bauer DE, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005; 8: 311-321. (Pubitemid 41443416)
13. Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010; 107: 2037-2042.
14. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007; 11: 37-51. (Pubitemid 46054520)
15. Cao W, Yacoub S, Shiverick KT, et al. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate. 2008; 68: 1223-1231.
16. Michelakis ED, Webster L, Mackey JR,. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008; 99: 989-994.
17. Wang JB, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010; 18: 207-219.
18. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452: 230-233. (Pubitemid 351380249)
19. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E,. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005; 15: 300-308. (Pubitemid 41058775)
20. Dombrauckas JD, Santarsiero BD, Mesecar AD,. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry. 2005; 44: 9417-9429. (Pubitemid 40962040)
21. Hitosugi T, Kang S, Vander Heiden MG, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009; 2: ra73.
22. Lv L, Li D, Zhao D, et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell. 2011; 42: 719-730.
23. Anastasiou D, Yu Y, Israelsen WJ, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012; 8: 839-847.
24. Walsh MJ, Brimacombe KR, Anastasiou D, et al. ML265: A potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda, MD: National Center for Biotechnology Information; 2010-2012 Mar 16 [updated 2013 May 8].
25. Lee J, Kim HK, Han YM, Kim J,. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell Biol. 2008; 40: 1043-1054.
26. Luo W, Hu H, Chang R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011; 145: 732-744.
27. Yang W, Xia Y, Ji H, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature. 2011; 480: 118-122.
28. Ren F, Wu H, Lei Y, et al. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer. 2010; 9: 81.
29. Liu L, Wang S, Zhang Q, Ding Y,. Identification of potential genes/proteins regulated by Tiam1 in colorectal cancer by microarray analysis and proteome analysis. Cell Biol Int. 2008; 32: 1215-1222.
30. Hitosugi T, Zhou L, Elf S, et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell. 2012; 22: 585-600.
31. Tennant DA, Duran RV, Boulahbel H, Gottlieb E,. Metabolic transformation in cancer. Carcinogenesis. 2009; 30: 1269-1280.
32. Tennant DA, Duran RV, Gottlieb E,. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010; 10: 267-277.
33. Corcoran CA, Huang Y, Sheikh MS,. The regulation of energy generating metabolic pathways by p53. Cancer Biol Ther. 2006; 5: 1610-1613.
34. Evans MJ, Saghatelian A, Sorensen EJ, Cravatt BF,. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol. 2005; 23: 1303-1307. (Pubitemid 41486859)
35. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361: 1058-1066.
36. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-773.
37. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010; 207: 339-344.
38. Jin G, Reitman ZJ, Spasojevic I, et al. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One. 2011; 6: e16812.
39. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010; 465: 966.
40. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17: 225-234.
41. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18: 553-567.
42. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012; 483: 474-478.
43. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340: 626-630.
44. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013; 340: 622-626.
45. Ben Sahra I, Laurent K, Giuliano S, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010; 70: 2465-2475.
46. Wellen KE, Lu C, Mancuso A, et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev. 2010; 24: 2784-2799.
47. Metallo CM, Gameiro PA, Bell EL, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012; 481: 380-384.
48. Fan J, Hitosugi T, Chung TW, et al. Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol. 2011; 31: 4938-4950.
49. Hitosugi T, Fan J, Chung TW, et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell. 2011; 44: 864-877.
50. Hitosugi T, Zhou L, Fan J, et al. Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nat Commun. 2013; 4: 1790.